We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-4.8%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$724M
AUM Growth
+$565M
Cap. Flow
+$651M
Cap. Flow %
90.01%
Top 10 Hldgs %
43.31%
Holding
66
New
33
Increased
17
Reduced
2
Closed
14

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$64.2M
2
MRK icon
Merck
MRK
+$40.5M
3
MCK icon
McKesson
MCK
+$35.6M
4
ABBV icon
AbbVie
ABBV
+$32.6M
5
CAH icon
Cardinal Health
CAH
+$26.2M

Top Sells

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$13.8M
2
HCA icon
HCA Healthcare
HCA
+$9.27M
3
ZBH icon
Zimmer Biomet
ZBH
+$8.16M
4
EW icon
Edwards Lifesciences
EW
+$6.3M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$5.76M

Sector Composition

Rank Sector Weight
1 Healthcare 92.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
51
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.79M 0.25%
123,143
+83,143
+208% +$1.8M
COLL icon
52
Collegium Pharmaceutical
COLL
$1.18B
$278K 0.04%
17,000
-163,000
-91% -$3.36M
ABEO icon
53
Abeona Therapeutics
ABEO
$355M
– –
-53,000
Closed -$4.33M
BAX icon
54
Baxter International
BAX
$12.8B
– –
-165,000
Closed -$13.8M
DXCM icon
55
DexCom
DXCM
$29B
– –
-76,000
Closed -$4.16M
EW icon
56
Edwards Lifesciences
EW
$49.4B
– –
-81,000
Closed -$6.3M
EXAS
57
DELISTED
Exact Sciences
EXAS
– –
-31,000
Closed -$2.87M
HCA icon
58
HCA Healthcare
HCA
$88.4B
– –
-62,700
Closed -$9.27M
MDGL icon
59
Madrigal Pharmaceuticals
MDGL
$12.6B
– –
-15,000
Closed -$1.37M
NGNE icon
60
Neurogene
NGNE
$672M
– –
-10,500
Closed -$2.59M
NXTC icon
61
NextCure
NXTC
$20.4M
– –
-7,750
Closed -$5.24M
RCKT icon
62
Rocket Pharmaceuticals
RCKT
$343M
– –
-30,000
Closed -$683K
RLMD icon
63
Relmada Therapeutics
RLMD
$540M
– –
-10,000
Closed -$390K
ZBH icon
64
Zimmer Biomet
ZBH
$18.8B
– –
-56,135
Closed -$8.16M
AXNX
65
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-208,000
Closed -$5.76M
ARAV
66
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-30,000
Closed -$410K
1 2
3

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2020 Portfolio in Review

As of Q1 2020, Avidity Partners Management held 66 positions worth $724M, up 356% from $159M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Avidity Partners Management deployed $651M of net new capital in Q1 2020, opening 33 new positions and adding to 17 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 580,000 shares worth $66.9M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Collegium Pharmaceutical, an estimated $3.36M trimmed.

  • Avidity Partners Management's largest Q1 2020 buy was Seagen Inc. Common Stock: 580,000 shares worth $66.9M.
  • Avidity Partners Management added most to AbbVie in Q1 2020, an estimated $32.6M increase.
  • Avidity Partners Management's biggest Q1 2020 reduction was Collegium Pharmaceutical, cutting an estimated $3.36M.
  • Avidity Partners Management fully exited Baxter International in Q1 2020, selling an estimated $13.8M.
  • Avidity Partners Management's ten largest holdings make up 43% of its $724M portfolio in Q1 2020.
  • Avidity Partners Management opened 33 new positions and closed 14 in Q1 2020.
  • Avidity Partners Management's portfolio value rose 356% quarter-over-quarter to $724M.

Based on Avidity Partners Management's 13F filing for Q1 2020, filed 15 May 2020.